Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Genuine question which I’m sure has already been posted so forgive me if this is a repeat. What are the chances that Polygon are averaging down, releasing a RNs’ to encourage PI buy in with speculation of TO or JV with a large pharma and then they ditch all their stock once they meet their desired price?! Does anyone know of a similar scenario in the history of other stocks?
https://go.nature.com/3rhR8cSNot sure if this has already been posted. Lawrence Tabak (NIH Director) tweet: In ~10% of cases, #SARSCoV2 infection triggers oxygen-deficient #COVID19 pneumonia. New #NIH-funded research suggests insufficient type 1 IFN immunity in the respiratory tract may account for viral spread, leading to pulmonary & systemic inflammation.
Bline, you still haven’t addressed how you thought, from a medical POV, that my post was clueless? Interested to hear your scientific based take rather than your declaration against being a deramper. You’ve addressed one point now address the other. I’ll wait….
What I find intriguing is why involves CFDs at this point. Surely if time trickles on Polygon could build up nicely. So the question is why now? Is something happening behind the scenes at a pace that they don’t feel they have adequate time to build their percentage? Or indeed, if they want to ‘borrow’ voting rights, why now? I think the timing is more interesting than the what.
I’ve been interested in the number of new posters recently. The green boxes appear to be flourishing. Or indeed those who ‘are LTHs but just watch the board’. Those who claim to be LTHs but have apparently have no clue regarding much of the company’s activities (even though historically they appear to have posted previously regarding such matters).
Added to that the number of new posters who seem interested in the number of shares people have, what their average is and their opinions on JV/TO, it really has peaked my interest.
Just my thoughts.
With regards to your second point - intervening in someone who is ‘high risk’ yet may have ‘mild flu symptoms’ is really relevant to the stage of their infection. Target infection here and reduce the risk of multi system involvement which requires more intervention, more money and more inpatient care.
Do you treat every patient with ‘mild flu symptoms’, No. Do you make a calculated assessment of poor outcomes in those with known co-mobidities, yes.
Symptoms do not equal outcomes.
BBC news. Prof Andrew Pollard, head of the Oxford vaccine group commented on the plans for booster jabs.‘ Over time, there needed to be a move away from community testing of mild infections - which will boost people's immunity - to clinically-driven testing of people who become unwell, he added.The focus should be on improving treatment for people who become seriously ill from Covid in hospital, Prof Pollard said.’I think this highlights the need for testing of those who become ill and providing targeted therapies rather than wasting resources on those who generally have mild disease.
Considering this comment was made in the context if what studies are in which phase. He discussed Mabs in phase 3 and reference tablet based therapies ‘that are still in phase 2’. He then proceeds to discussing how SNG has ‘moved to phase 3’. I get the impression the cat is out of the bag….
You seemed to be aware of the difference between a P2 and a P3 last month in your post. This implies SNG may have progressed into a P3 within the Activ-2 trial. I’ve watched it 3 times and he had said ‘moved on to phase 3’. Any clinician I know would not have ‘misspoken’ in so much detail.